vimarsana.com

Latest Breaking News On - International prognostic scoring system - Page 1 : vimarsana.com

Luspatercept Generates Across-the-Board Benefit for Lower-Risk MDS in COMMANDS

Luspatercept elicited superior erythroid response rates and duration of RBC transfusion independence compared with epoetin alfa in lower-risk MDS.

SL-172154 Receives FDA Orphan Drug Designation in AML

Key Factors Significantly Associated With ESA Response in Lower-Risk MDS

Hemoglobin levels, transfusion independence, and low serum erythropoietin levels were all deemed to have a statistically significant relationship with erythropoiesis-stimulating agent (ESA) response.

FDA Drug Approval Decisions Expected in June 2024

FDA Drug Approval Decisions Expected in June 2024
psychiatryadvisor.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from psychiatryadvisor.com Daily Mail and Mail on Sunday newspapers.

Dr Ball on Data From from the IMerge Trial in Low– to Intermediate-Risk MDS

Dr Ball on Data From from the IMerge Trial in Low– to Intermediate-Risk MDS
onclive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from onclive.com Daily Mail and Mail on Sunday newspapers.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.